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Abstract: Electron-deficient half-sandwich complexes are a class of 
under-studied organometallics with demonstrated potential as 
metallodrug candidates. The present study investigates the effect of 
two 16-electron organoruthenium complexes ([(p-cym)Ru(benzene-
1,2-dithiolato)] (1) and [(p-cym)Ru(maleonitriledithiolate)] (2)) on the 
cell viability of non-immortalised human lymphocytes from healthy 
individuals. The genotoxic effects of 1 and 2 in lymphocytes using the 
Comet and cytokinesis-block micronucleus assays is also 
investigated. Gene expression studies were carried out on a panel of 
genes involved in apoptosis and DNA damage repair response. 
Results show that the two 16-electron complexes do not have 
significant effect on the cell viability of human lymphocytes from 
healthy individuals. However, an increase in DNA damage is induced 
by both compounds, presumably through oxidative stress production. 
Introduction 
Reactive oxygen species (ROS) are oxygen-containing molecules 
which are constantly produced as byproducts from various cell 
functions such as cellular respiration and production of energy. 
Additionally, ROS can be generated as a result of exposure to 
irradiation, air pollutants, and toxic substances. Among the most 
important ROS within living organisms are species such as the 
superoxide (O2•-) and hydroxyl (HO•) free radicals, and hydrogen 
peroxide (H2O2).[1] In order to survive oxidative stress, living 
organisms need to have a well-coordinated system which copes 
with stressors and high levels of generated ROS. Alterations in 
oxidative stress have been shown to be particularly effective 
against cancer cells,[2] which, owing to their active metabolism, 
are under constant oxidative stress.[3]  
Nonetheless, the role of ROS in cancer is debatable and there 
has been an ongoing discussion whether or when ROS have a 
tumour-promoting or tumour-suppressive effect. Through pro-
tumourigenic signaling, ROS promote cancer cell proliferation, 
survival, and adaptation to hypoxia. On the other hand, through 
anti-tumourigenic signaling these radicals induce oxidative stress 
followed by cell death. The two contradicting functions of ROS 
depend on the nature of the free radicals, their concentration, and 
their location. For instance, when the intracellular level of ROS is 
modest, this can contribute to tumour promotion.[4] However, 
when the level of ROS is high, this can lead to cellular damage 
and tumour suppression.[5] Additionally, location is a very 
important factor for determining ROS function as mitochondrial 
ROS have been shown to induce cell death, while NOX-generated 
ROS have been linked to cell proliferation and migration (NOX 
enzymes being ROS-producing NADPH oxidases, found in most 
eukaryotic organisms).[6] The role of antioxidants in cancer 
treatment is also complicated as it can involve either protection of 
normal cells from toxic radicals, or stimulation of tumour growth. 
In normal cells, antioxidants prevent the formation of 
malignancies,[7] while in developed tumours antioxidants 
contribute to cell growth, enhance resistance mechanisms, and 
interfere with ROS-dependent anticancer therapies.[8] Current 
strategies for the treatment of cancer through modulation of the 
redox balance include ROS-depleting therapy with the use of 
antioxidants, or ROS-elevating therapy which involves the 
increase of intracellular ROS levels either directly or through the 
inhibition of antioxidant systems. 
We recently reported the highly-promising in vitro anticancer 
properties of two electron-deficient half-sandwich complexes ([(p-
cym)Ru(benzene-1,2-dithiolato)] (1) and [(p-
cym)Ru(maleonitriledithiolate)] (2); Figure 1).[9] These two 
complexes are air- and moisture-stable and unreactive towards 
N-, S-, or O-donor ligands. Complex 1 exhibits significantly high 
cytotoxicity against colorectal cancer cell lines (12 to 34  more 
potent than cisplatin, IC50 values in the nanomolar range), and 
high in vitro selectivity (>50-fold) towards the cancer cells tested, 
compared to PNT2 normal cells. In vitro complex 2 was found to 
be highly cytotoxic with IC50 values in the nanomolar range: 5 to 
60 times more potent than cisplatin towards some ovarian, colon, 
and lung cancer cell lines. It showed no cross-resistance and, 
unlike cisplatin, the remarkable in vitro antiproliferative activity of 
this compound appears to be p53-independent. In vivo evaluation 
with the hollow-fibre assay across a panel of cancer cell types and 
subcutaneous H460 non-small cell lung cancer xenograft model 
hinted at the activity of the complex in mice. The ability of 
complexes 1 and 2 to generate ROS production and oxidative 
stress in cancer cells was demonstrated by co-incubation with the 
antioxidant molecule N-acetylcysteine and by using the 
fluorescent DCFH2-DA assay and flow cytometry.[9] 
In our efforts to evaluate the anticancer potential of such electron-
deficient half-sandwich complexes, the toxicity of complexes 1 
and 2 against human lymphocytes from healthy individuals is 
reported herein; the aim of this study being to confirm the 
surprising selectivity we previously observed for these complexes 
between cancer and normal, immortalised, cells. In this work, we 
used non-immortalised healthy lymphocytes isolated from freshly-
taken blood to assess the toxicity of these complexes. The DNA 
damage induced by these compounds using the Comet and 
cytokinesis-block micronucleus assays was also investigated, in 
order to reinforce our hypothesis that oxidative stress is an 
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such complexes. In general, DNA responses to damage could be 
variable depending on the types of cells examined. However, we 
believe that primary human cells freshly isolated ex-vivo/in-vitro 
are the best surrogate model to examine responses in human, 
owing to their intact metabolic system. 
Results and Discussion 
Chemosensitivity assay 
 
Complexes 1 and 2 were synthesised according to previously-
reported methods with slight variations (see Experimental 
Section).[9] Their stability in the media necessary for treatment of 
lymphocytes was first tested. Owing to their poor water solubility 
at millimolar concentrations, the complexes were dissolved in 
pure deuterated dimethylsulfoxide (DMSO-d6) (1 mM 
concentration) and 1H NMR spectra at t = 0 h and 24 h were 
recorded. The complexes are stable under these conditions, 
although a slight loss of para-cymene can be observed (free p-
cym signals at ca. 7.2 ppm) after 24 hours (Figure 1). Nonetheless, 
both complexes are stable in pure DMSO at millimolar 
concentration and they are expected to be stable at micromolar 
concentration in the drug-media solutions which are added to cells 
(the final DMSO concentrations being less than 0.5% (v/v) in all 
cases). Both compounds are stable in a mixture RPMI drug-
media/DMSO (1/1; v/v) at ambient temperature over a minimum 
of 72 hours, as determined by UV-visible spectroscopy (Figure 
S1).  
 
Figure 1. Molecular structures and stability studies in DMSO-d6 of complexes 1 
and 2. 
Chemosensitivity studies were then undertaken using a Cell 
Counting Kit-8 (CCK-8; see Experimental Section). Cell viability 
was determined against isolated human lymphocytes from 
healthy individuals exposed for 24 h to either complex 1 or 2 at 
concentrations of 1, 2, 3, 4 and 5 µM (higher concentrations than 
the IC50 values determined for both complexes against cancer 
cells, in the nanomolar range). Both compounds were shown to 
have no significant or little effect on the cell viability of human 
lymphocytes (Figure 2). This result is not only in accordance with 
our preliminary investigations on the cytotoxicity of 1 and 2 
against normal PNT2 cells, but also demonstrates the absence of 
cytotoxicity towards healthy, non-immortalised, isolated 
lymphocytes from blood samples taken by venipuncture from 
healthy control individuals within the University of Bradford.  
 
Figure 2. Cell viability of isolated human lymphocytes treated with either 
complex 1 or 2. Data represent the means ± SD obtained from three repetitions. 
DNA damage studies 
 
The responses of lymphocytes from healthy individuals to 1 for 
the Comet assay parameters (Olive tail moment (OTM) and % tail 
DNA) are shown in Figures 3, S2, and Tables S1 and S2. The tail 
moment is defined as the product of the tail length and the fraction 
of total DNA present in the tail. This also includes measurements 
of smallest detectable size of migrating fragmented DNA and 
relaxed and broken pieces of DNA. Tail length is used to describe 
the distance of DNA migration from the body of the nuclear core 
region (the head of comet) and is used to evaluate the extent of 
DNA damage. 
 
A significant increase from 0.84 (OTM) 5.74 (% tail DNA) to 2.63 
(OTM) and 12.70 (% tail DNA) can be observed when increasing 
the complex concentration from 0 to 3 µM. Further significant 
increase of both parameters can be observed with higher 
concentrations of 1 with a maximum of 4.23 (OTM) and 20.20 (% 
tail DNA) when using 5 µM. Similarly, when cells are treated with 
complex 2, an increase from 0.86 (OTM) and 6.61 (% tail DNA) to 
2.72 (OTM) and 13.92 (% tail DNA) can be observed when raising 
the concentration from 0 to 3 µM. Cells treated with 5 µM showed 
an even greater increases to 5.19 (OTM) and 22.29 (% tail DNA). 
Both complexes 1 and 2 show a similar increase in DNA damage 












Figure 3. DNA damage measured as mean OTM and % tail DNA after treatment 
of human lymphocytes from healthy individuals with 1 and 2 (0, 1, 2, 3, 4, 5 µM) 
for 30 minutes. Data represent the means ± SE obtained from three repetitions. 
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To confirm the results obtained by the Comet assay, chromosome 
damage induced by 1 and 2 was determined by assessing the 
frequencies of micronuclei (MNi). After treating the cells with 3 µM 
of either complex 1 or 2, a significant increase of the MNi can be 
observed, which indicates DNA damage. Increasing 
concentrations of either compound also correlates with an 
increase of MNi frequencies (Table 1). Thus, the extent of DNA 
damage by the Comet assay was reflected by the CBMN assay. 
Table 1. Cytological scoring parameters, including cell mitotic status (BiNC, and 
MultiNC), NDI and chromosomal damage/instability parameters in the form of 
NPBs and NBUDs in lymphocytes following exposure to complexes 1 and 2. 
Data represent the mean ± SE obtained from healthy individuals 







BiMN             BiBuds 
BiNPB 
Mean of 
% MNi in 
MoNC 
Complex 1        
Untreated 1.8 56.6 12.1 1.66 0 0 0 
1µM 1.9 59.6 10.6 3.0 0 0 1.0 
2µM 1.8 47.3 11.2 4.3 0 0 1.0 
3µM 1.6 51.8 10.0 10.3*** 0 0 4.0 
4µM 1.8 47.3 13.0 12.0*** 1.0 0 4.3 
5µM 2.0 62.0 13.60 15.3*** 2.1 1 11.6 
Complex 2        
Untreated 1.8 62.0 9.1 2.0 0 0 1.0 
1µM 1.9 59.6 8.6 3.3 0 0 1.0 
2µM 1.9 60.0 14.1 4.0 0 0 2.1 
3µM 1.9 63.1 13.1 9.0*** 0 0 6.6 
4µM 2.0 62.0 13.3 13.0*** 1.0 0 8.0 
5µM 2.0 69.1 12.1 16.0*** 2.5 2.1 14.6 
NDI = Nuclear division index, BiNC = Binucleated cells, % BiNC, is % expressed 
out of all types of 500 cells scored; MonoNC = Mononucleated cells. MultiNC = 
Multinucleated cells % MultiNC, is % expressed out of all types of 500 cells 
scored. MNi = Micronuclei score/500 cells each of BiNC and MonoN; NPBs = 
Nucleoplasmic bridges and NBUDs = Nuclear buds. ***p < 0.001 versus 
untreated cells. 
Evaluations of DNA damage induced by half-sandwich ruthenium 
compounds using the Comet assay or the cytokinesis-blocked 
micronucleus assay have been previously reported.[10] In most 
cases, such complexes had the capacity to covalently bind to 
nucleobases and DNA, in a similar manner than cisplatin; DNA 
damage is therefore not unexpected.[10-11] In the present study, 
both complexes 1 and 2 induce DNA damage, whereas they were 
previously demonstrated to be not capable of binding DNA 
covalently due to their unique properties as stable pseudo 16-
electron species.[9, 12] Other ruthenium(II) complexes such as 
[Ru(bipy)2(dppz)]PF6 or [Ru(dmb)2(1-Ph-βC)]+, where dppz = 
dipyrido[3,2-a:2’,3’-c]phenazine, 1-Ph-βC = 1-phenyl-9H-
pyrido[3,4-b]indole, dmb = dimethylbipyridine, have also been 
shown to produce DNA damage despite binding to DNA non 
covalently or not binding due to low affinity.[13]  
Gene expression studies 
 
Gene expression studies were carried out on a panel of genes 
involved in apoptosis and DNA damage repair response (Figure 
4): p53, known as guardian of the genome, whose role is 
preserving the stability and preventing genome mutations; p21, 
associated with linking DNA damage and cell cycle arrest; and 
BCL2 involved in regulation of apoptosis. Below 3 μM, 
compounds 1 and 2 do not show any significant effect on gene 
expressions. Above 3 μM (>> IC50 values on cancer cells), 
compound 2 shows a significant increase in p53 and p21 gene 
expressions, consistent with genome damage. Additionally, a 
downregulation of BCL2 can also be observed indicating pro-
activation of apoptosis. In contrast, at concentrations of 4 and 5 
µM of compound 1 in cells, a 1.3 x times reduction of the mRNA 
p53 and p21 levels was observed. This clear 3 μM threshold 
indicates that healthy cells can recover well from the stress 
induced by the two compounds at concentrations much higher 
than the previously determined half-maximal inhibitory 
concentrations on cancer cells, but that above 3 µM genotoxicity 
starts being observed. We believe that this observation supports, 
and certainly does not disprove, our hypothesis of oxidative stress 












Figure 4. Effect of 1 and 2 on the P53, P21 and BCL2 mRNA expression levels 
in human lymphocytes. Values were normalized using β-actin as an internal 
control. Data from three different healthy individuals (n=3) in triplicate. *p<0.05 
and ***P < 0.001 compared with untreated lymphocytes. 
Conclusion 
In conclusion, the data presented herein demonstrate that the two 
electron-deficient half-sandwich complexes [(p-cym)Ru(benzene-
1,2-dithiolato)] (1) and [(p-cym)Ru(maleonitriledithiolate)] (2) do 
not present a significant toxicity against healthy, non-immortalised, 
isolated lymphocytes from blood samples taken by venipuncture 
from healthy control individuals. Furthermore, although not able 
to covalently bind to nucleobases, these complexes induce a 
significant DNA damage response in such lymphocytes, as 
demonstrated by the Comet and the cytokinesis-blocked 
miconucleus assays. This study, combined with our previous 
results obtained on generation of ROS species and apoptosis, 
suggests that the cytotoxicity of complexes 1 and 2 against cancer 
cells may come from their ability to generate a high-enough 
oxidative stress in cells to cause apoptosis in cancer cells but a 
low-enough level to allow normal and healthy cells to recover. We 
believe that such results are valuable and encouraging for the 
future development of electron-deficient organometallics as 
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Materials and instrumentation 
Metals chloride hydrates were purchased from Precious Metals Online. All 
other reagents were obtained from commercial suppliers and used as 
received. Dichloromethane was dried over molecular sieves 4Å. All 
procedures were performed under nitrogen atmosphere and with pre-dried 
glassware, unless otherwise stated. All reagents used in the different tests 
were purchased from Sigma-Aldrich Company Ltd. (Sigma Chemical Ltd., 
Gillingham, UK). 
Synthesis 
[(p-cym)Ru(benzene-1,2-dithiolato)] (1): Ruthenium dimer [(p-cym)RuCl2]2 
(100 mg, 0.16 mmol) was placed in a 50 mL 2-neck round bottom flask 
and dissolved in 20 mL of dry dichloromethane. Benzene-1,2-dithiolato (40 
mg, 0.34 mmol) dissolved in dry dichloromethane (5 mL) was then added 
dropwise to the solution containing the ruthenium dimer. The dark red 
mixture was then left stirring under a nitrogen atmosphere at room 
temperature for 1 h. After removing the solvent under vacuum, a dark 
precipitate was obtained. The crude product was purified by 
chromatography (hexane/dichloromethane 1:2 v/v). 
[(p-cym)Ru(maleonitriledithiolate)] (2): Ruthenium dimer [(p-cym)RuCl2]2 
(150 mg, 0.25 mmol) and disodium maleonitriledithiolate (100 mg, 0.50 
mmol) were placed in a 50 mL 2-neck round bottom flask and dissolved in 
20 mL of dry dichloromethane. The dark brown mixture was then left 
stirring under a nitrogen atmosphere at room temperature for 1 h. After 
removing the solvent under vacuum, a dark precipitate was obtained. The 
crude product was purified immediately by chromatography 
(dichloromethane). 
Stability studies 
Complexes 1 and 2 were dissolved in DMSO-d6 (1.1 mM) and 1H NMR 
spectra (400 MHz, 298 K) were recorded over a period of 24 h. Complexes 
1 and 2 were dissolved in DMSO-d6 were dissolved in DMSO/RPMI (1/1; 
v/v) at ambiant temperature (5 × 10-5 M) and UV-visible spectra were 
recorded over a period of 72 h. 
Collection of blood samples  
After informed consent, approximately 10 mL heparinised blood was taken 
by venepuncture from the healthy control individuals within the University 
of Bradford, UK (West Yorkshire, UK). Ethical permission was obtained 
from Leeds East Ethics Committee (Reference no: 12/YH/0464) and the 
University of Bradford’s Sub-Committee for Ethics in Research involving 
Human Subjects (Reference no.: 0405/8).  
Isolation of lymphocytes  
Three mL of whole blood were diluted 3:3 with 0.9% saline and carefully 
layered on top of three mL of Lymphoprep in 15 mL Falcon tubes. The 
tubes were centrifuged for 20 min at 800 × g. Lymphocytes were then 
harvested, washed with saline (10 mL) and centrifuged again for 15 min at 
500 × g at room temperature. Lymphocytes were re-suspended in Roswell 
Park Memorial Institute (RPMI) 1640 Medium and used for the in vitro 
experiments. 
Chemosensitivity assay 
The cytotoxicity assay using the Cell Counting Kit-8 (CCK-8) was 
performed to determine the effect of 1 and 2 on the cellular viability of 
isolated human lymphocytes. Isolated cells were plated in a 96-well plate 
at a concentration of 5000 cells per well. Cells were either treated with 
different concentrations of 1 and 2 of 1, 2, 3, 4 and 5 µM or left untreated 
and considered as control for 24 h in a humidified incubator at 37° C, 5% 
CO2. Ten microliters of CCK-8 solution were added to each well of the 
plate, followed by incubation at 37 °C for 4 h. Absorbance was measured 
at a wavelength of 450 nm using a Microplate reader MRX II (Dynex 
Technologies, Chantilly, USA). Viability was also measured by the trypan 
blue exclusion test indicating intact cell membranes.[14] Ten microliters of 
0.05% trypan blue was added to 10 μL of cell suspension and the 
percentage of cells excluding the dye was estimated using an improved 
Neubauer haemocytometer.[15] 
Comet assay 
Cell suspensions (1 mL, 106 cells/mL) were mixed with fresh RPMI 1640 
medium (total volume 1 L). To each treatment tube, 100 mL of cell 
suspension, 890 mL of RPMI 1640 medium and 10 µL of 1 or 2 or RPMI 
were added. Untreated lymphocytes from healthy individuals served as the 
negative control group. Cells were treated with different concentrations of 
0, 1, 2, 3, 4, 5 µM of 1 and 2 for 30 min in a humidified incubator at 37 °C, 
5% CO2. After treatment, the cells were used for the Comet assay to detect 
DNA damage (single and double-strand breaks in DNA, alkali-labile sites 
and oxidative base damage). 
The Comet assay was processed with slight modifications according to the 
literature.[16] In brief, the lymphocytes were mixed with prewarmed 0.5 % 
low melting agarose (LMP) (Invitrogen, Paisley, UK: 15517-022). The cell 
suspension was then transferred to slides pre-coated with 1% normal 
melting point (NMP) agarose and covered with a coverslip. The slides were 
solidified on an ice block for 5 min. The coverslip was removed, and the 
slides incubated in cold lysing buffer (2.5 M NaCl, 100 mM EDTA, 10 mM 
Tris, pH 10, with 1% Triton X-100 and 10% DMSO were added just before 
use) and kept overnight at 4 °C. The slides were placed on a horizontal gel 
electrophoresis platform to allow the DNA to unwind in cold fresh 
electrophoresis buffer (300 mM NaOH and 1 mM Na2EDTA, pH ∼13.5) at 
4°C, and electrophoresis was performed at 4°C for 30 min. The slides were 
neutralised with a 400 mM Tris (pH 7.5) buffer for 5 min. The slides were 
stained with ethidium bromide and covered with a coverslip. Slides were 
examined by a computerised image analysis system (Comet 6.0; Andor 
Technology, Belfast, UK). One hundred cells were scored per sample (50 
cells from each slide); Olive tail moment (OTM) and % tail DNA were 
measured as DNA damage parameters.  
The cytokinesis-block micronucleus (CBMN) assay 
CBMN was performed as described in the literature with modifications.[16b, 
16c, 17] Five hundred microliters of whole blood were added to a T25 cm2 
Corning culture flask containing 4.5 mL RPMI 1640 medium supplemented 
with 1% of penicillin-streptomycin, 15% foetal bovine serum, 25 mM 
HEPES and L-glutamine with a final concentration of 15 and 1%, 
respectively, followed by 100 μL of phytohemagglutinin (PHA). In the next 
24 h, 50 μL of excipient (original solution) was added to the negative 
control. Different concentrations of 1 and 2 of 1, 2, 3, 4, 5 µM were added 
to the rest of the flasks. Cultures were incubated at 37°C in the presence 
of 5% CO2 for 44 h. After 44 h, cytochalasin-B (6 μg/mL, Sigma) was added 
and the cultures were incubated for another 28 h. The CBMN test 
preparations and slides scored were performed using the criteria, as 
recommended by Fenech et al. [18]. Micronuclei (MNi) were scored each 
from binucleated (BiNC) and mononucleated (MonoNC) cells. Other 
nuclear anomalies such as nucleoplasmic bridges (NPBs) and nuclear 
buds (NBUDs) were also evaluated as biomarkers of genotoxic events. 
The nuclear division index (NDI) was used as an indicator of the 
cytotoxicity and the following calculation was used to find the NDI: NDI = 
(M1 + 2 (M2) + 3 (M3) /N. Where: M1 = mononucleated cells, M2 = 
binucleated cells, M3 = multinucleated cells, N = the total number of viable 
cells scored.[17] 














This article is protected by copyright. All rights reserved.
FULL PAPER    
5 
 
Cell suspensions (1 mL, 106 cells/mL) were mixed with fresh RPMI medium 
(total volume 1 L). To each treatment tube, 100 mL of cell suspension, 890 
mL RPMI medium and 10 µL of 1 or 2 or RPMI were added. Untreated 
lymphocytes from healthy individuals served as the negative control group. 
Cells were treated with different concentrations of 0, 1, 2, 3, 4, 5 µM of 1 
and 2 for 24 h in a humidified incubator at 37 oC, 5% CO2.  
Total RNA was extracted from lymphocytes using the GenElute 
Mammalian Total RNA Purification kit (Sigma-Aldrich, UK). The RNA was 
treated with DNase I (Sigma-Aldrich, UK) to remove any DNA 
contaminants. The concentration and purity of total RNA were determined 
by measuring the absorbance at 260 and 280 nm (A260/280) ratios, using a 
NanoDrop™ Spectrophotometer.  
Real-time PCR  
RNA was reverse transcribed using the iScript™ cDNA Synthesis Kit (Life 
Science Research, Bio-Rad). The reactions were performed using the 
StepOnePlus™ real-time PCR instrument (Applied Biosystems). The 
qPCR was used to measure the mRNA expression level of P53, P21 and 
BCL2 in lymphocytes. Each reaction was prepared in triplicate and 
consisted of 10 µL of 10 × SYBR® Green PCR Master Mix (Applied 
Biosystems), 12.5 pmol each of forward and reverse primers, and 2 μL of 
cDNA template, making up to a 20 µL final volume per well. The qPCR 
was initially conducted at 50°C and 95°C for 2 and 20s, respectively, 
followed by amplification of the template for 40 cycles (each cycle involved 
15 s at 95°C and 30s at 60°C). The data were analysed by StepOne™ 
Software v 2.2.2. The cycle threshold (Ct) mean value for the target gene 
was used to calculate the relative expression with the relative 
quantification (RQ) value and formula: RQ = 2-ΔCT × 100, where 
ΔCT = CT of target gene - CT of an endogenous housekeeping gene. 
Evaluation of 2-ΔCT indicates the fold change in gene expression, 
normalized to the internal control (β-actin) which enables the comparison 
between differently treated cells.  
Statistical Analysis 
All the experiments were performed in duplicate and repeated at least 
three times. Results are expressed as means ± SEM of three experiments 
and data were analysed using one-way analysis of variance with Dunnett’s 
post hoc test to determine significance relative to control; for all 
experiments, a P value of <0.05 was considered significant. 
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